Fundus Autofluorescence Imaging

FAF may be recommended when you report gradual central vision loss, difficulty reading or recognizing faces, distortion of straight lines, colors that appear faded or washed out, or a slowly enlarging blind spot in the center of your vision. These symptoms can reflect changes in the RPE layer that FAF is specifically designed to detect. It is also important to know that many patients with abnormal FAF findings have no symptoms at all, which is one reason this imaging tool is so valuable as an early detection method.

An optometrist or ophthalmologist may refer a patient for FAF imaging after noticing drusen (small yellow deposits that form beneath the retina), pigment changes in the macula, or other retinal abnormalities during a dilated eye exam. FAF helps characterize these findings more precisely, which guides decisions about whether closer monitoring or specialist evaluation is needed.

Patients already diagnosed with a retinal condition often undergo FAF imaging at regular intervals to track how the disease is evolving over time. For geographic atrophy in dry AMD, FAF is considered one of the most reliable tools for measuring the rate of RPE cell loss. For inherited retinal diseases, serial FAF imaging shows whether the area of functioning retina is stable or gradually shrinking, which helps guide counseling and ongoing care planning.

Geographic atrophy (GA) is an advanced form of dry AMD in which areas of RPE cells are permanently lost. FAF is one of the most reliable tools for identifying GA and measuring how quickly it is expanding over time. Specific FAF patterns surrounding zones of atrophy, such as banded, diffuse, or patchy areas of increased brightness, have been shown to predict the rate at which atrophy may spread. This information helps guide decisions about treatment and how closely a patient should be monitored over time.

Wet AMD involves the growth of abnormal blood vessels beneath the retina and is a distinct condition from dry AMD that requires different management. In wet AMD, FAF can reveal peripheral retinal changes and RPE damage that may not be visible on OCT alone. This additional information may influence monitoring schedules for patients receiving anti-VEGF injections, which are medications that suppress abnormal blood vessel growth. Anti-VEGF therapy is specific to wet AMD and is not a treatment for dry AMD or geographic atrophy.

Stargardt disease is the most common inherited macular dystrophy, caused by mutations in the ABCA4 gene that lead to abnormal lipofuscin buildup in the RPE. FAF is considered the gold-standard imaging test for this condition and clearly shows the characteristic pattern of bright flecks and central areas of dark atrophy that define the disease. Serial FAF imaging over months and years helps track how the condition is progressing and provides important information for ongoing care planning.

Retinitis pigmentosa is a group of inherited diseases that cause progressive narrowing of peripheral vision. FAF in these conditions typically reveals a ring of increased brightness marking the boundary between functioning retina and areas of damage. The size of this ring has been correlated with the amount of remaining visual field. As the ring contracts inward over time, peripheral vision continues to narrow. Regular FAF monitoring helps retina specialists assess the rate of progression and counsel patients appropriately.

For patients on long-term hydroxychloroquine therapy, FAF can detect a characteristic ring pattern of increased autofluorescence in the macula that signals early RPE toxicity. This finding is especially valuable because it may appear before changes become detectable on visual field testing or OCT. Identifying toxicity at this early stage allows the prescribing physician and retina specialist to consider adjusting or discontinuing the medication before irreversible vision loss occurs.

FAF is a safe, non-invasive test that involves no injections, dyes, or contact with the eye. The low-intensity light used during the test does not harm the retina. The only temporary effects come from the dilating drops, which cause blurry near vision and light sensitivity for a few hours. If you have a history of narrow-angle glaucoma or a prior reaction to dilating drops, let the technician know before the test so your care team can take appropriate precautions.

Fluorescein angiography requires an injection of fluorescent dye into a vein in the arm. That dye travels through the bloodstream and highlights blood vessel activity in the retina, which is especially useful for evaluating wet AMD, retinal vein occlusions, and other vascular conditions. FAF requires no injection and instead captures the natural fluorescence of lipofuscin already present in the RPE cells. The two tests provide different but complementary information, and your retina specialist may order one or both depending on what clinical questions need to be answered.

The answer depends on the condition being monitored and how quickly it appears to be progressing. Patients with geographic atrophy typically have FAF every six to twelve months to measure the rate of atrophy expansion. Those taking hydroxychloroquine may have annual FAF imaging after an initial baseline exam. For inherited retinal diseases, intervals vary based on disease activity and severity. Your retina specialist will design a monitoring schedule tailored to your specific situation, and that schedule may be adjusted over time as new information becomes available.

Yes, and this early detection capability is one of FAF's most important strengths. In conditions such as early hydroxychloroquine toxicity, early AMD, and inherited retinal diseases, FAF can reveal abnormal patterns months or even years before vision loss begins. Identifying these changes at an early stage gives your retina specialist and prescribing physician more time to adjust treatment, increase monitoring frequency, or plan other interventions before irreversible damage occurs.

Some general ophthalmologists and optometrists have FAF-capable equipment and may perform the test as part of a routine visit. However, accurately interpreting complex FAF patterns and making sound treatment decisions based on those findings requires the depth of training that a fellowship-trained retina specialist brings. If your eye care provider identifies a concerning finding on FAF or suspects a condition that FAF might help evaluate, a referral to a retina specialist is the appropriate next step for thorough evaluation and management.

Coverage for FAF imaging varies by insurance plan and by the medical reason the test is ordered. When FAF is requested to evaluate a diagnosed retinal condition or to monitor established risk factors, coverage is often available at least in part. Our staff can help verify your benefits and answer questions about coverage when you schedule your appointment.